MX2014005433A - Métodos y composiciones para modular bacterias gastrointestinales para promover la salud. - Google Patents

Métodos y composiciones para modular bacterias gastrointestinales para promover la salud.

Info

Publication number
MX2014005433A
MX2014005433A MX2014005433A MX2014005433A MX2014005433A MX 2014005433 A MX2014005433 A MX 2014005433A MX 2014005433 A MX2014005433 A MX 2014005433A MX 2014005433 A MX2014005433 A MX 2014005433A MX 2014005433 A MX2014005433 A MX 2014005433A
Authority
MX
Mexico
Prior art keywords
proportion
compositions
composition
methods
disease
Prior art date
Application number
MX2014005433A
Other languages
English (en)
Spanish (es)
Inventor
Thomas W Boileau
Jennifer Brulc
Ravindranath Sreedhar Menon
Original Assignee
Gen Mills Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Mills Inc filed Critical Gen Mills Inc
Publication of MX2014005433A publication Critical patent/MX2014005433A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
    • A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
    • A23L7/126—Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MX2014005433A 2011-11-04 2012-11-01 Métodos y composiciones para modular bacterias gastrointestinales para promover la salud. MX2014005433A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555800P 2011-11-04 2011-11-04
PCT/US2012/063008 WO2013067146A1 (en) 2011-11-04 2012-11-01 Methods and compositions for modulating gastrointestinal bacteria to promote health

Publications (1)

Publication Number Publication Date
MX2014005433A true MX2014005433A (es) 2014-08-22

Family

ID=48192757

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005433A MX2014005433A (es) 2011-11-04 2012-11-01 Métodos y composiciones para modular bacterias gastrointestinales para promover la salud.

Country Status (11)

Country Link
US (1) US20150209383A1 (cg-RX-API-DMAC7.html)
EP (1) EP2773357A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014532710A (cg-RX-API-DMAC7.html)
KR (1) KR20140093252A (cg-RX-API-DMAC7.html)
CN (1) CN104159588A (cg-RX-API-DMAC7.html)
AU (1) AU2012332491A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014010660A2 (cg-RX-API-DMAC7.html)
CA (1) CA2854398A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN04055A (cg-RX-API-DMAC7.html)
MX (1) MX2014005433A (cg-RX-API-DMAC7.html)
WO (1) WO2013067146A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201312713D0 (en) * 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
GB2551642B (en) 2014-10-31 2020-09-23 Pendulum Therapeutics Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3283087A4 (en) * 2015-04-14 2019-03-13 Ubiome Inc. METHOD AND SYSTEM FOR MICROBIOMEDIVED DIAGNOSTICS AND THERAPEUTICS FOR DISEASES OF THE ENDOCRINE SYSTEM
WO2016183535A1 (en) 2015-05-14 2016-11-17 University Of Puerto Rico Methods for restoring microbiota of newborns
GB201519088D0 (en) * 2015-10-28 2015-12-09 Metabogen Ab The use of bacteria formulations
WO2017117142A1 (en) 2015-12-28 2017-07-06 New York University Device and method of restoring microbiota of newborns
CN106994136A (zh) * 2016-01-26 2017-08-01 富士胶片株式会社 肠内细菌数量抑制剂、食品、及药品
SG11201807616RA (en) * 2016-03-14 2018-10-30 B Food Science Co Ltd Proliferative agent for faecalibacterium
EP3511406A4 (en) * 2016-09-06 2020-04-01 BGI Shenzhen FAECALIBACTERIUM LONGUM AND APPLICATION THEREOF
EP3630146A1 (en) 2017-06-02 2020-04-08 Goodgut S.L. Grape skin for use in the treatment of dysbiosis
AU2018326705A1 (en) 2017-08-30 2020-03-05 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
EP3466417A1 (en) * 2017-10-04 2019-04-10 Sorbonne Université Compounds for the prevention and treatment of glucose intolerance related conditions and obesity
CA3088630A1 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
CN109998112B (zh) * 2017-12-22 2024-05-14 奥地利商艾尔柏有限公司 红蝽杆菌纲促进肠道健康的用途
EP3752167A1 (en) * 2018-02-14 2020-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Polydextrose for the treatment of inflammatory diseases
EP3790997A4 (en) * 2018-05-09 2022-03-16 Carbiotix AB METHOD FOR MEASURING AND IMPROVING INTESTINAL HEALTH
US11376289B2 (en) 2018-05-31 2022-07-05 Bgi Shenzhen Composition and uses thereof
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
CA3111795A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
ES2763874B2 (es) * 2018-11-30 2020-10-13 Consejo Superior Investigacion Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades
EP4041264A1 (en) * 2019-10-07 2022-08-17 Siolta Therapeutics, Inc. Therapeutic pharmaceutical compositions
KR102174095B1 (ko) * 2019-12-11 2020-11-05 주식회사 에이치이엠 신규한 엔테로코커스 패시움 hem 200 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물
WO2021184008A1 (en) * 2020-03-13 2021-09-16 Fitbiomics Inc. Probiotic compositions for improving human health and athletic performance
JP2021168651A (ja) * 2020-04-16 2021-10-28 サンスター株式会社 フィーカリバクテリウム属細菌増殖用組成物、酪酸産生増加用組成物、及び腸内環境改善用組成物
JP2024518270A (ja) * 2021-05-06 2024-05-01 ソシエテ・デ・プロデュイ・ネスレ・エス・アー イノシトール、エリスリトール、又はソルビトールのうちの少なくとも１つを使用した、フィーカリバクテリウム・プラウスニッツィイの生育を増進するための組成物及び方法
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0394655A (ja) * 1989-09-06 1991-04-19 Otsuka Pharmaceut Co Ltd 栄養補給用組成物
JP4328473B2 (ja) * 2001-04-09 2009-09-09 雪印乳業株式会社 肥満予防改善飲食品
FI20020078A7 (fi) * 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
JP2003334025A (ja) * 2002-05-15 2003-11-25 Toyo Shinyaku:Kk 健康食品
JP2005534315A (ja) * 2002-08-06 2005-11-17 ダニスコ エイ／エス 食品および薬学的組成物中に細胞外多糖類を産生する乳酸桿菌の使用
GB0302872D0 (en) * 2003-02-10 2003-03-12 Univ Liverpool Treatment of inflammatory bowel disease
US20080292766A1 (en) * 2007-05-23 2008-11-27 Hoffman Andrew J Edible Composition Comprising a Slowly Digestible or Digestion Resistant Oligosaccharide Composition
GB0903016D0 (en) * 2009-02-23 2009-04-08 Univ Gent Method for alleviating intestinal problems and novel bacterial strains therefor
US8816067B2 (en) * 2009-05-07 2014-08-26 Tate & Lyle Ingredients France SAS Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans

Also Published As

Publication number Publication date
CN104159588A (zh) 2014-11-19
EP2773357A1 (en) 2014-09-10
IN2014CN04055A (cg-RX-API-DMAC7.html) 2015-10-23
WO2013067146A1 (en) 2013-05-10
AU2012332491A1 (en) 2014-05-29
JP2014532710A (ja) 2014-12-08
EP2773357A4 (en) 2015-08-26
BR112014010660A2 (pt) 2017-05-09
CA2854398A1 (en) 2013-05-10
US20150209383A1 (en) 2015-07-30
KR20140093252A (ko) 2014-07-25

Similar Documents

Publication Publication Date Title
MX2014005433A (es) Métodos y composiciones para modular bacterias gastrointestinales para promover la salud.
Liu et al. Gut microbiota: A new target for T2DM prevention and treatment
Li et al. Probiotic mixture of Lactobacillus plantarum strains improves lipid metabolism and gut microbiota structure in high fat diet-fed mice
Quezada et al. Acemannan and fructans from Aloe vera (Aloe barbadensis Miller) plants as novel prebiotics
Mu et al. Naringin attenuates high fat diet induced non-alcoholic fatty liver disease and gut bacterial dysbiosis in mice
Fan et al. Research progress of gut microbiota and obesity caused by high-fat diet
Zou et al. Rice bran attenuated obesity via alleviating dyslipidemia, browning of white adipocytes and modulating gut microbiota in high-fat diet-induced obese mice
Yuan et al. Punicic acid ameliorates obesity and liver steatosis by regulating gut microbiota composition in mice
Zhang et al. Changes in intestinal microbiota of type 2 diabetes in mice in response to dietary supplementation with instant tea or matcha
Shang et al. Characterization of fecal fat composition and gut derived fecal microbiota in high-fat diet fed rats following intervention with chito-oligosaccharide and resistant starch complexes
Singh et al. Gut microbiome as a novel cardiovascular therapeutic target
Zhou et al. Gut microbiota might be a crucial factor in deciphering the metabolic benefits of perinatal genistein consumption in dams and adult female offspring
JP2015523362A5 (cg-RX-API-DMAC7.html)
MX2012012777A (es) Agentes de union del receptor nuclear.
Kobyliak et al. Comparative experimental investigation on the efficacy of mono-and multiprobiotic strains in non-alcoholic fatty liver disease prevention
WO2011097273A8 (en) Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine
WO2010081079A3 (en) Composition and method for treatment of diabetes
WO2010136900A3 (en) Methods of using krill oil to treat risk factors for metabolic disorders and obesity
MX2012003459A (es) Composicion y metodo para el tratamiento de la diabetes.
Fabbiano et al. Host–microbiota mutualism in metabolic diseases
Li et al. The mulberry-derived 1-deoxynojirimycin (DNJ) inhibits high-fat diet (HFD)-induced hypercholesteremia and modulates the gut microbiota in a gender-specific manner
Liu et al. Salidroside protects mice from high-fat diet-induced obesity by modulating the gut microbiota
Yang et al. Enhancing flora balance in the gastrointestinal tract of mice by lactic acid bacteria from Chinese sourdough and enzyme activities indicative of metabolism of protein, fat, and carbohydrate by the flora
Aldamarany et al. Perilla, sunflower, and tea seed oils as potential dietary supplements with anti-obesity effects by modulating the gut microbiota composition in mice fed a high-fat diet
WO2011087857A3 (en) Compositions and methods for treating obesity and diabetes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal